CLAIMS

1. A cyclic peptide compound or the stereoisomer thereof, characterized in that the cyclic peptide compound has a structure represented by formula I-1,

AA3-AA1-AA2-GLY-HIS-LYS

Formula I-1

wherein:

AA1 is selected from the group consisting of a phenylalanine residue, an alanine residue, a methionine residue, a leucine residue, a tryptophan residue, an isoleucine residue, a proline residue, and a glycine residue;

AA2 is selected from the group consisting of an alanine residue, a methionine residue, a leucine residue, a tryptophan residue, an isoleucine residue, a proline residue, and a valine residue;

AA3 is selected from the group consisting of a phenylalanine residue, an alanine residue, a methionine residue, a leucine residue, an isoleucine residue, and a valine residue;

* indicates that the N-terminus and the C-terminus of the formula I-1 are linked to form a cyclic peptide;

the amino acid is of D-configuration or L-configuration, preferably of L-configuration.

2. The cyclic peptide compound or the stereoisomer thereof of claim 1, characterized in that AA1 is selected from the group consisting of a methionine residue, an alanine residue, a phenylalanine residue, a glycine residue, and a proline residue.

3. The cyclic peptide compound or the stereoisomer thereof of claim 1 or 2, characterized in that AA2 is selected from the group consisting of a proline residue, a leucine residue, a valine residue, and a tryptophan residue.

4. The cyclic peptide compound or the stereoisomer thereof of any one of claims 1-3, characterized in that AA2 is selected from the group consisting of a leucine residue, and a tryptophan residue.

5. The cyclic peptide compound or the stereoisomer thereof of any one of claims 1-4, characterized in that AA3 is selected from the group consisting of a phenylalanine residue, an alanine residue, a methionine residue, and a leucine residue.

6. The cyclic peptide compound or the stereoisomer thereof of any one of claims 1-5, characterized in that AA1 is selected from the group consisting of a methionine residue, an alanine residue, a phenylalanine residue, and a proline residue.

7. The cyclic peptide compound or the stereoisomer thereof of any one of claims 1-6, characterized in that the structural formula of the cyclic peptide compound is selected from the group consisting of:

SEQ ID NO:	The structural formula of the cyclic peptide compound
292	LEU PHE LEU GLY HIS LYS

710	VAL PRO TRP GLY HIS LYS
205	ILE MET PRO GLY HIS LYS
340	MET GLY PRO GLY HIS LYS
250	LEU ALA PRO GLY HIS LYS
52	ALA PHE PRO GLY HIS LYS
414	PHE ALA VAL GLY HIS LYS
214	ILE PHE PRO GLY HIS LYS
297	LEU PHE VAL GLY HIS LYS
289	LEU PHE ALA GLY HIS LYS
291	LEU PHE ILE GLY HIS LYS
196	ILE LEU PRO GLY HIS LYS
232	ILE TRP PRO GLY HIS LYS
268	LEU ILE PRO GLY HIS LYS
707	VAL PRO MET GLY HIS LYS
341	MET GLY TRP GLY HIS LYS
665	VAL GLY TRP GLY HIS LYS
386	MET PRO TRP GLY HIS LYS
337	MET GLY LEU GLY HIS LYS
256	LEU GLY LEU GLY HIS LYS
40	ALA MET LEU GLY HIS LYS
202	ILE MET LEU GLY HIS LYS
49	ALA PHE LEU GLY HIS LYS
283	LEU MET LEU GLY HIS LYS
169	ILE ALA PRO GLY HIS LYS
247	LEU ALA LEU GLY HIS LYS
382	MET PRO LEU GLY HIS LYS
220	ILE PRO LEU GLY HIS LYS
286	LEU MET PRO GLY HIS LYS

wherein all amino acids are of L-configuration.

8. A pharmaceutical composition comprising the cyclic peptide compound or the stereoisomer thereof of any one of claims 1-7;

optionally, further comprising at least one carrier and/or excipient.

9. A cosmetic composition comprising the cyclic peptide compound or the stereoisomer thereof of any one of claims 1-7;

optionally, further comprising a functional substance;

preferably, the functional substance being one or more selected from the group consisting of skin conditioning agents, antioxidants, surfactants, humectants, preservatives, chelating agents, and flavor essences.

10. Use of the cyclic peptide compound or the stereoisomer thereof of any one of claims 1-7 or the pharmaceutical composition of claim 8 in the manufacture of a medicament which is used for one or more selected from the following (1) - (7):

(1) delaying skin aging;

(2) reducing skin damage;

(3) accelerating skin wound healing;

(4) reducing hyperpigmentation;

(5) stimulating hair growth;

(6) improving the success rate of hair transplantation;
(7) preventing hair loss.

11. Use of the cyclic peptide compound or the stereoisomer thereof of any one of claims 1-7 or the cosmetic composition of claim 9 in one or more selected from the following (1) - (17):
(1) anti-aging of the skin;
(2) anti-wrinkling of the skin and reducing fine lines;
(3) improving mechanical properties of the skin: firmness, complexion, elasticity, and/or flexibility;
(4) increasing skin density;
(5) increasing skin volume;
(6) combating the appearance of stretch marks;
(7) reducing skin damage;
(8) accelerating skin wound healing;
(9) anti-spot;
(10) improving skin homogeneity and/or luster;
(11) reducing skin pigmentation;
(12) moisturizing;
(13) stimulating hair growth;
(14) improving the success rate of hair transplantation;
(15) preventing hair loss;
(16) topical cosmetology of eyelashes;
(17) increasing hair width, density, and/or length.